Author

D. Hany

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

D. Picard· 3 shared K. Bhattacharya· 2 shared D. Wider· 1 shared L. Bernasconi· 1 shared M. Zoetemelk· 1 shared N. Hulo· 1 shared O. Panasenko· 1 shared P. Nowak-Sliwinska· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Picard

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Hsf1 and the molecular chaperone Hsp90 support a "rewiring stress response" leading to an adaptive cell size increase in chronic stress

S. Maiti, K. Bhattacharya, D. Wider, D. Hany, O. Panasenko, L. Bernasconi, N. Hulo, D. Picard

The paper shows that chronic mild stress leads to adaptive cell size increase through Hsf1 and Hsp90, enhancing resilience to persistent stress.

bioRxiv · Jan 25, 2023Cell Biology

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer

D. Hany, M. Zoetemelk, K. Bhattacharya, P. Nowak-Sliwinska, D. Picard

The paper identifies effective low-dose multidrug combinations for ER+/HER2-/PI3Kα-mutant breast cancer using network analysis and experimental validation.

bioRxiv · Aug 30, 2022Cancer Biology

CRISPR/Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells

D. Hany, V. Vafeiadou, D. Picard

The paper identifies PAICS as a driver of tamoxifen resistance in ER+ breast cancer by promoting estrogen-independent ER activity through cAMP-PKA and mTOR pathways, suggesting combined targeting of PAICS and ER as a therapeutic strategy.

bioRxiv · Jun 3, 2022Cancer Biology